1. Home /
    2. Altai Protocol Library /
  2. New Indication: Adjuvant nivolumab for esophageal / GE junction cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Adjuvant nivolumab for esophageal / GE junction cancer

New Indication: Adjuvant nivolumab for esophageal / GE junction cancer
Study:
  • Randomized, double-blind phase III trial (CheckMate 577)
  • Esophageal or GE junction cancer (adeno or SCC) pts who received neoadjuvant chemoRT => undergone R0 resection during which pathological residual disease was found
  • Adjuvant nivolumab vs. placebo x 1 year or until disease progression
Efficacy:
  • Median DFS: 22.4 vs. 11.0 mos (HR: 0.69 [0.56-0.86])
  • Median distant metastasis-free survival: 28.3 vs. 17.6 mos (HR: 0.74 [0.60-0.92])
Safety:
  • Grade >=3 AEs: fatigue (1% vs. <1%), diarrhea (<1% vs. <1%), rash (<1% vs. <1%)

N Engl J Med 2021;384:1191-203.

Kelly RJ, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

https://doi.org/10.1056/NEJMoa2032125

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More